Gemcitabine/cisplatin vs MVAC. Results after 5 years of the phase III study on the chemotherapy of advanced urothelial cancer in Germany;Gemcitabin/cisplatin vs. MVAC: 5-Jahres-ergebnisse der phase-III-studie zur chemotherapie des fortgeschrittenen urothelkarzinoms in Deutschland

Urologe - Ausgabe A

Volumn 42, Issue 8, 2003, Pages 1074-1086

  Lehmann, J ^a   Retz, M ^b   Steiner, G ^b   Albers, P ^b   Jaeger, E ^b   Knuth, A ^b   Lippert, C ^b   Koser, M ^b   Stockamp, K ^b   Otto, C ^b   Melchior, H ^b   Fassmann C ^b   Potratz, C ^b   Loch, T ^b   Derigs, H G ^b   Becker, T ^b   Kalble T ^b   Piechota, H J ^b   Hertle, L ^b   Weinknecht, S ^b   Weissbach L ^b   Al Mwalad, M ^b   Hamza, A ^b   Henss H ^b   Brkovic, D ^b   Pomer, S ^b   Roloff, J ^b   Walz, P ^b   Muschter, R ^b   Tunn, U ^b   Winter, E ^b   Bub, P ^b   Kaldenbach, U ^b   Roth, S ^b   Brauers, A ^b   Jakse, G ^b   Richter, A E ^b   Wirth, M ^b   Hartlapp, J ^b   Van Ahlen, H ^b   Stockle M ^b   more..

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

Advanced of metastatic transitional cell carcinoma; Bladder cancer; Chemotherapy toxicity; Gemcitabine cisplatin; MVAC; Systemic chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DIARRHEA; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; GERMANY; HUMAN; INFECTION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEPHROURETERECTOMY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROGNOSIS; THROMBOCYTOPENIA; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE; UROLOGIC NEOPLASMS; VINBLASTINE;

EID: 10744233028     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0317-4     Document Type: Article

References (28)

1. Albers P, Siener R, Härtlein M et al. (2002) Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 25:47-52
2. Bajorin DF, Dodd PM, Mazumdar M et al. (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181
3. Cox DR (1972) Regression models and life tables with discussion. J R Statistic Soc B 34:187-220
4. Feldman SE, Klinger E (1963) Short cut calculation of the Fisher-Yates "exact test". Psychometrika 28: 289-291
5. Gebbia V, Testa A, Borsellino N et al. (1999) Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 150: 11-15
6. Herr HW, Donat SM, Bajorin DF (2001) Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165:811-814
7. Kaufman D, Raghavan D, Carducci M et al. (2000) Phase II trial ofgemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927
8. Lippert CM, Rhein A, Rabs U, Koser M, Wechsel H, Becht E (2002) First-line Chemotherapie des Urothelkarzinoms im Stadium IV mit Gemcitabin und Cisplatin im 21-tägigen Regime (AUO Studie 17/98). Urologe A 41: 68
9. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066-1073
10. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1055
11. Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M (2000) Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter triai. J Urol 164:53-56
12. Lorusso V, Pollera CF, Antimi M et al.(1998) A phase II study ofgemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208-1212
13. Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist 18:50-60
14. Moore MJ, Tannock IF, Ernst DS, Huan 5, Murray N (1997) Gemcitabine:a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445
15. Moore MJ, Winquist EW, Murray N et al. (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876-2881
16. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. JASA 53:457-481
17. Peto R, Pike MC, Armitage P et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39
18. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115
19. Pollera CF, Ceribelli A, Crecco M, Cala bresi F (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182-184
20. Saxman SB, Propert KJ, Einhom LH et al. (1997) Long-term follow-up ofa phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564-2569
21. Siefker-Radtke A, Walsh G, Swanson D, Logothetis C, Millikan R (2002) Is there a role for surgery in the management of metastatic urothelial cancer? An update of the M.D.Anderson experience. J Urol 167[Suppl]:283
22. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398
23. Sternberg CN, Yagoda A, Scher HI et al. (1985) Preliminary results of M-VAC (methotrexate, vin blastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407
24. Sweeney P, Millikan R, Wood C, Pettaway C, Donat M, Grossman B, Pisters L (2002) Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection (RPLND) in metastatic transitional cell carcinoma (TCC) of the bladder? J Urol 167 [Suppl]:283
25. Ventriglia MO, Cabrera Aguilar LR, Varcasia D, Fayad E, Carlevari J, Maidana M, Estevez RA (2001) A phase II study of gemcitabine and cisplatin in elderly patients with advanced bladder cancer. Proc Am Soc Clin Oncol 20:199
26. von der Maase H (2001) Gemcitabine-containing regimens in bladder cancer: A new standard of care. Semin Oncol 28:1-3
27. von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L (1999) Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10:1461-1465
28. von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin versus methotrexate, vin blastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077